Is Bloom Energy The Best Stock to Buy Now?
Shares of energy startup Bloom Energy (NYSE:BE) have advanced by…
Sell
44
NVCR Quote, Financials, Valuation and Earnings
Last price:
$13.17
Seasonality move
:
-11.64%
Day range:
$12.80 - $13.97
52-week range:
$10.70 - $32.06
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
2.31x
P/B ratio:
4.41x
Volume:
1.4M
Avg. volume:
1.9M
1-year change:
-56.36%
Market cap:
$1.5B
Revenue:
$605.2M
EPS (TTM):
-$1.61
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
$158.9M | -$0.42 | 4.75% | -35.35% | $24.79 |
|
CATX
Perspective Therapeutics, Inc.
|
$206.8K | -$0.32 | -9.65% | -37.91% | $12.3077 |
|
LIVN
LivaNova Plc
|
$342.3M | $0.92 | 9.75% | -20.8% | $70.64 |
|
VNRX
VolitionRX Ltd.
|
$715.6K | -$0.05 | 272.5% | -33.67% | $2.20 |
|
VTAK
Catheter Precision, Inc.
|
$310K | -$0.20 | 118.75% | -11.57% | -- |
|
XTNT
Xtant Medical Holdings, Inc.
|
$32.7M | -- | -2.42% | -100% | $1.50 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
$13.44 | $24.79 | $1.5B | -- | $0.00 | 0% | 2.31x |
|
CATX
Perspective Therapeutics, Inc.
|
$2.8500 | $12.3077 | $211.9M | -- | $0.00 | 0% | 193.24x |
|
LIVN
LivaNova Plc
|
$63.05 | $70.64 | $3.4B | 38.16x | $0.00 | 0% | 2.56x |
|
VNRX
VolitionRX Ltd.
|
$0.27 | $2.20 | $32.8M | -- | $0.00 | 0% | 18.33x |
|
VTAK
Catheter Precision, Inc.
|
$1.86 | -- | $2.3M | 0.40x | $0.00 | 0% | 8.74x |
|
XTNT
Xtant Medical Holdings, Inc.
|
$0.81 | $1.50 | $113.4M | 79.41x | $0.00 | 0% | 0.88x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
70.04% | -1.015 | 55.15% | 1.44x |
|
CATX
Perspective Therapeutics, Inc.
|
1.35% | 3.691 | 1.3% | 8.47x |
|
LIVN
LivaNova Plc
|
29.6% | 1.882 | 17.01% | 1.05x |
|
VNRX
VolitionRX Ltd.
|
-48.16% | 2.566 | 15.4% | 0.04x |
|
VTAK
Catheter Precision, Inc.
|
68.63% | -0.348 | 537.37% | 0.41x |
|
XTNT
Xtant Medical Holdings, Inc.
|
39.2% | 2.955 | 35.76% | 1.08x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NVCR
NovoCure Ltd.
|
$122.5M | -$36M | -16.67% | -50.08% | -21.54% | $14.9M |
|
CATX
Perspective Therapeutics, Inc.
|
-$566K | -$27.9M | -37.13% | -37.63% | -13330.62% | -$18.3M |
|
LIVN
LivaNova Plc
|
$244.9M | $56.6M | -12.15% | -18.29% | 15.83% | $62.2M |
|
VNRX
VolitionRX Ltd.
|
$318.2K | -$5.1M | -- | -- | -813.17% | -$3.5M |
|
VTAK
Catheter Precision, Inc.
|
-$320K | -$3M | -79.27% | -192.05% | -1336.73% | -$2.2M |
|
XTNT
Xtant Medical Holdings, Inc.
|
$22M | $2.5M | 2.15% | 3.78% | 7.64% | $4.2M |
NovoCure Ltd. vs. Competitors
-
Which has Higher Returns NVCR or CATX?
Perspective Therapeutics, Inc. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of -12425.36%. NovoCure Ltd.'s return on equity of -50.08% beat Perspective Therapeutics, Inc.'s return on equity of -37.63%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B CATXPerspective Therapeutics, Inc.-270.81% -$0.35 $245.5M -
What do Analysts Say About NVCR or CATX?
NovoCure Ltd. has a consensus price target of $24.79, signalling upside risk potential of 84.42%. On the other hand Perspective Therapeutics, Inc. has an analysts' consensus of $12.3077 which suggests that it could grow by 331.85%. Given that Perspective Therapeutics, Inc. has higher upside potential than NovoCure Ltd., analysts believe Perspective Therapeutics, Inc. is more attractive than NovoCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 CATXPerspective Therapeutics, Inc.12 1 0 -
Is NVCR or CATX More Risky?
NovoCure Ltd. has a beta of 0.825, which suggesting that the stock is 17.463% less volatile than S&P 500. In comparison Perspective Therapeutics, Inc. has a beta of 1.222, suggesting its more volatile than the S&P 500 by 22.249%.
-
Which is a Better Dividend Stock NVCR or CATX?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Perspective Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. Perspective Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or CATX?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than Perspective Therapeutics, Inc. quarterly revenues of $209K. NovoCure Ltd.'s net income of -$37.3M is lower than Perspective Therapeutics, Inc.'s net income of -$26M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while Perspective Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.31x versus 193.24x for Perspective Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.31x -- $167.2M -$37.3M CATXPerspective Therapeutics, Inc.193.24x -- $209K -$26M
-
Which has Higher Returns NVCR or LIVN?
LivaNova Plc has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of 7.49%. NovoCure Ltd.'s return on equity of -50.08% beat LivaNova Plc's return on equity of -18.29%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B LIVNLivaNova Plc68.44% $0.49 $1.6B -
What do Analysts Say About NVCR or LIVN?
NovoCure Ltd. has a consensus price target of $24.79, signalling upside risk potential of 84.42%. On the other hand LivaNova Plc has an analysts' consensus of $70.64 which suggests that it could grow by 12.03%. Given that NovoCure Ltd. has higher upside potential than LivaNova Plc, analysts believe NovoCure Ltd. is more attractive than LivaNova Plc.
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 LIVNLivaNova Plc6 2 0 -
Is NVCR or LIVN More Risky?
NovoCure Ltd. has a beta of 0.825, which suggesting that the stock is 17.463% less volatile than S&P 500. In comparison LivaNova Plc has a beta of 1.020, suggesting its more volatile than the S&P 500 by 2.023%.
-
Which is a Better Dividend Stock NVCR or LIVN?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. LivaNova Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. LivaNova Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or LIVN?
NovoCure Ltd. quarterly revenues are $167.2M, which are smaller than LivaNova Plc quarterly revenues of $357.8M. NovoCure Ltd.'s net income of -$37.3M is lower than LivaNova Plc's net income of $26.8M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while LivaNova Plc's PE ratio is 38.16x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.31x versus 2.56x for LivaNova Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.31x -- $167.2M -$37.3M LIVNLivaNova Plc2.56x 38.16x $357.8M $26.8M
-
Which has Higher Returns NVCR or VNRX?
VolitionRX Ltd. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of -862.39%. NovoCure Ltd.'s return on equity of -50.08% beat VolitionRX Ltd.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B VNRXVolitionRX Ltd.50.73% -$0.05 -$24.7M -
What do Analysts Say About NVCR or VNRX?
NovoCure Ltd. has a consensus price target of $24.79, signalling upside risk potential of 84.42%. On the other hand VolitionRX Ltd. has an analysts' consensus of $2.20 which suggests that it could grow by 722.43%. Given that VolitionRX Ltd. has higher upside potential than NovoCure Ltd., analysts believe VolitionRX Ltd. is more attractive than NovoCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 VNRXVolitionRX Ltd.4 2 0 -
Is NVCR or VNRX More Risky?
NovoCure Ltd. has a beta of 0.825, which suggesting that the stock is 17.463% less volatile than S&P 500. In comparison VolitionRX Ltd. has a beta of 1.258, suggesting its more volatile than the S&P 500 by 25.804%.
-
Which is a Better Dividend Stock NVCR or VNRX?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. VolitionRX Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. VolitionRX Ltd. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or VNRX?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than VolitionRX Ltd. quarterly revenues of $627.3K. NovoCure Ltd.'s net income of -$37.3M is lower than VolitionRX Ltd.'s net income of -$5.4M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while VolitionRX Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.31x versus 18.33x for VolitionRX Ltd.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.31x -- $167.2M -$37.3M VNRXVolitionRX Ltd.18.33x -- $627.3K -$5.4M
-
Which has Higher Returns NVCR or VTAK?
Catheter Precision, Inc. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of -1037.17%. NovoCure Ltd.'s return on equity of -50.08% beat Catheter Precision, Inc.'s return on equity of -192.05%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B VTAKCatheter Precision, Inc.-141.59% -$1.70 $21.3M -
What do Analysts Say About NVCR or VTAK?
NovoCure Ltd. has a consensus price target of $24.79, signalling upside risk potential of 84.42%. On the other hand Catheter Precision, Inc. has an analysts' consensus of -- which suggests that it could grow by 1943.07%. Given that Catheter Precision, Inc. has higher upside potential than NovoCure Ltd., analysts believe Catheter Precision, Inc. is more attractive than NovoCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 VTAKCatheter Precision, Inc.0 0 0 -
Is NVCR or VTAK More Risky?
NovoCure Ltd. has a beta of 0.825, which suggesting that the stock is 17.463% less volatile than S&P 500. In comparison Catheter Precision, Inc. has a beta of -1.301, suggesting its less volatile than the S&P 500 by 230.084%.
-
Which is a Better Dividend Stock NVCR or VTAK?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catheter Precision, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. Catheter Precision, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or VTAK?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than Catheter Precision, Inc. quarterly revenues of $226K. NovoCure Ltd.'s net income of -$37.3M is lower than Catheter Precision, Inc.'s net income of -$2.3M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while Catheter Precision, Inc.'s PE ratio is 0.40x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.31x versus 8.74x for Catheter Precision, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.31x -- $167.2M -$37.3M VTAKCatheter Precision, Inc.8.74x 0.40x $226K -$2.3M
-
Which has Higher Returns NVCR or XTNT?
Xtant Medical Holdings, Inc. has a net margin of -22.29% compared to NovoCure Ltd.'s net margin of 3.93%. NovoCure Ltd.'s return on equity of -50.08% beat Xtant Medical Holdings, Inc.'s return on equity of 3.78%.
Company Gross Margin Earnings Per Share Invested Capital NVCRNovoCure Ltd.73.25% -$0.33 $1.1B XTNTXtant Medical Holdings, Inc.66.13% $0.01 $82.9M -
What do Analysts Say About NVCR or XTNT?
NovoCure Ltd. has a consensus price target of $24.79, signalling upside risk potential of 84.42%. On the other hand Xtant Medical Holdings, Inc. has an analysts' consensus of $1.50 which suggests that it could grow by 85.19%. Given that Xtant Medical Holdings, Inc. has higher upside potential than NovoCure Ltd., analysts believe Xtant Medical Holdings, Inc. is more attractive than NovoCure Ltd..
Company Buy Ratings Hold Ratings Sell Ratings NVCRNovoCure Ltd.4 2 0 XTNTXtant Medical Holdings, Inc.2 0 0 -
Is NVCR or XTNT More Risky?
NovoCure Ltd. has a beta of 0.825, which suggesting that the stock is 17.463% less volatile than S&P 500. In comparison Xtant Medical Holdings, Inc. has a beta of -0.052, suggesting its less volatile than the S&P 500 by 105.153%.
-
Which is a Better Dividend Stock NVCR or XTNT?
NovoCure Ltd. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Xtant Medical Holdings, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NovoCure Ltd. pays -- of its earnings as a dividend. Xtant Medical Holdings, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NVCR or XTNT?
NovoCure Ltd. quarterly revenues are $167.2M, which are larger than Xtant Medical Holdings, Inc. quarterly revenues of $33.3M. NovoCure Ltd.'s net income of -$37.3M is lower than Xtant Medical Holdings, Inc.'s net income of $1.3M. Notably, NovoCure Ltd.'s price-to-earnings ratio is -- while Xtant Medical Holdings, Inc.'s PE ratio is 79.41x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NovoCure Ltd. is 2.31x versus 0.88x for Xtant Medical Holdings, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NVCRNovoCure Ltd.2.31x -- $167.2M -$37.3M XTNTXtant Medical Holdings, Inc.0.88x 79.41x $33.3M $1.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Berkshire Hathaway Stock Undervalued?
Berkshire Hathaway (NYSE:BRK.A,BRK.B) has undershot the market this year, returning…
Is Oracle Stock Undervalued?
Shares of Oracle (NYSE:ORCL) rocketed higher earlier this year when…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
59
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Buy
60
AAOI alert for Dec 23
Applied Optoelectronics, Inc. [AAOI] is up 4.05% over the past day.
Buy
52
ABVX alert for Dec 23
Abivax SA [ABVX] is up 0.41% over the past day.
Buy
60
ZBIO alert for Dec 23
Zenas BioPharma, Inc. [ZBIO] is up 1.02% over the past day.
